Autoimmune polyendocrine syndrome natural history, complications and prognosis: Difference between revisions
Irfan Dotani (talk | contribs) No edit summary |
No edit summary |
||
Line 3: | Line 3: | ||
{{CMG}}; {{AE}} | {{CMG}}; {{AE}} | ||
==Overview== | |||
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3]. | |||
OR | |||
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3]. | |||
OR | |||
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%. | |||
== | ==Natural History, Complications, and Prognosis== | ||
==Natural History== | ===Natural History=== | ||
*The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___. | |||
*The symptoms of (disease name) typically develop ___ years after exposure to ___. | |||
*If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3]. | |||
==Complications== | ===Complications=== | ||
*Common complications of [disease name] include: | |||
**[complication 1] | |||
**[complication 2] | |||
**[complication 3] | |||
==Prognosis== | ==Prognosis== | ||
Line 17: | Line 33: | ||
'''Type III:''' Prognosis of autoimmune polyendocrine syndrome type III depends on whether glandular failures occur or not. | '''Type III:''' Prognosis of autoimmune polyendocrine syndrome type III depends on whether glandular failures occur or not. | ||
===Prognosis=== | |||
*Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%. | |||
*Depending on the extent of the [tumor/disease progression/etc.] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent. | |||
*The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy]. | |||
*[Subtype of disease/malignancy] is associated with the most favorable prognosis. | |||
*The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis. | |||
==References== | ==References== | ||
{{Reflist|2}} | {{Reflist|2}} | ||
{{WH}} | |||
{{WS}} | |||
{{ | |||
{{ |
Revision as of 19:12, 14 August 2017
Autoimmune polyendocrine syndrome Microchapters |
Differentiating Autoimmune polyendocrine syndrome from other Diseases |
---|
Diagnosis |
Treatment |
Case Studies |
Autoimmune polyendocrine syndrome natural history, complications and prognosis On the Web |
American Roentgen Ray Society Images of Autoimmune polyendocrine syndrome natural history, complications and prognosis |
FDA on Autoimmune polyendocrine syndrome natural history, complications and prognosis |
CDC on Autoimmune polyendocrine syndrome natural history, complications and prognosis |
Autoimmune polyendocrine syndrome natural history, complications and prognosis in the news |
Blogs on Autoimmune polyendocrine syndrome natural history, complications and prognosis |
Directions to Hospitals Treating Autoimmune polyendocrine syndrome |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief:
Overview
If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
OR
Common complications of [disease name] include [complication 1], [complication 2], and [complication 3].
OR
Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
Natural History, Complications, and Prognosis
Natural History
- The symptoms of (disease name) usually develop in the first/ second/ third decade of life, and start with symptoms such as ___.
- The symptoms of (disease name) typically develop ___ years after exposure to ___.
- If left untreated, [#]% of patients with [disease name] may progress to develop [manifestation 1], [manifestation 2], and [manifestation 3].
Complications
- Common complications of [disease name] include:
- [complication 1]
- [complication 2]
- [complication 3]
Prognosis
Type I: The prognosis of autoimmune polyendocrine syndrome type I is variable, depending on how organs are affected and the severity of the disease.
Type II: Prognosis of autoimmune polyendocrine syndrome type II depends on whether endocrine end-organ failures occur or not.
Type III: Prognosis of autoimmune polyendocrine syndrome type III depends on whether glandular failures occur or not.
Prognosis
- Prognosis is generally excellent/good/poor, and the 1/5/10-year mortality/survival rate of patients with [disease name] is approximately [#]%.
- Depending on the extent of the [tumor/disease progression/etc.] at the time of diagnosis, the prognosis may vary. However, the prognosis is generally regarded as poor/good/excellent.
- The presence of [characteristic of disease] is associated with a particularly [good/poor] prognosis among patients with [disease/malignancy].
- [Subtype of disease/malignancy] is associated with the most favorable prognosis.
- The prognosis varies with the [characteristic] of tumor; [subtype of disease/malignancy] have the most favorable prognosis.